Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14130869 | 0.84 | MAPT (0.45) | TP53GAAMAPTALDH1A1HPGD | |
| SCHEMBL7905297 | 0.83 | PDE2A (0.45) | TP53GAAMAPTALDH1A1HPGD | |
| SCHEMBL11065049 | 0.80 | DRD1 (0.56) | TP53GAAMAPTALDH1A1HPGD | |
| SCHEMBL18746248 | 0.79 | NPC1 (0.53) | TP53GAAMAPTNPC1MAPK1 | |
| SCHEMBL20563547 | 0.79 | PPARG (0.49) | TP53MAPTALDH1A1HPGDNPC1 | |
| SCHEMBL799946 | 0.79 | NR1H4 (0.57) | MAPTALDH1A1HPGDNPC1MAPK1 | |
| SCHEMBL18494698 | 0.78 | TP53 (0.40) | TP53GAACACNA1HNR1H4APP | |
| SCHEMBL31125249 | 0.78 | ALDH1A1 (0.48) | TP53GAAMAPTALDH1A1HPGD | |
| SCHEMBL10837776 | 0.78 | ALOX15 (0.43) | TP53GAAMAPTNPC1MAPK1 | |
| SCHEMBL10467057 | 0.77 | DRD1 (0.42) | TP53GAAMAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025903-A1 | Bicyclic Compounds and Uses Thereof for the Treatment of Diseases | ATHIRA PHARMA, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025903-A1 | Bicyclic Compounds and Uses Thereof for the Treatment of Diseases | ATHIRA PHARMA, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | SAIL BIOMEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | SAIL BIOMEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230331705-A1 | Fused Imidazole Derivatives as AHR Antagonists | SENDA BIOSCIENCES, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331705-A1 | Fused Imidazole Derivatives as AHR Antagonists | SENDA BIOSCIENCES, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | SENDA BIOSCIENCES, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20090275620-A1 | SUBSTITUTED 5- PHENYLAMINO- 1, 3, 4-OXADIAZOL-2-YLCARBONYLAMINO-4-PHENOXY-CYCLOHEXANE CARBOXYLIC ACID AS INHIBITORS OF ACETYL COENZYME A DIACYLGLYCEROL ACYLTRANSFERASE | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275620-A1 | SUBSTITUTED 5- PHENYLAMINO- 1, 3, 4-OXADIAZOL-2-YLCARBONYLAMINO-4-PHENOXY-CYCLOHEXANE CARBOXYLIC ACID AS INHIBITORS OF ACETYL COENZYME A DIACYLGLYCEROL ACYLTRANSFERASE | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090118500-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090069400-A1 | Indole Sulfonamide Modulators of Progesterone Receptors | ELI LILLY AND COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | disclosed |
| US-7402674-B2 | 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH, (DE) | 2008-07-22 | — | — | US | disclosed |
| US-7402674-B2 | 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH, (DE) | 2008-07-22 | — | — | US | disclosed |
| US-20080070910-A1 | Therapeutic compounds and methods | GILEAD SCIENCES, INC. | 2008-03-20 | — | — | US | disclosed |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275620-A1 | SUBSTITUTED 5- PHENYLAMINO- 1, 3, 4-OXADIAZOL-2-YLCARBONYLAMINO-4-PHENOXY-CYCLOHEXANE CARBOXYLIC ACID AS INHIBITORS OF ACETYL COENZYME A DIACYLGLYCEROL ACYLTRANSFERASE | ACAT2, ACAT1, DGAT1 | TP53 3601/4885GAA 317/4885MAPT 3051/4885 |
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | AHR, ARNT, AIPL1 | TP53 311/4885GAA 3823/4885MAPT 4722/4885 |
| US-20090118500-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | TEK, MPL, THPO | TP53 1067/4885GAA 3533/4885MAPT 411/4885 |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | AHR, CD274, ARNT | TP53 40/4885GAA 3760/4885MAPT 4740/4885 |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, PDE2A | TP53 4655/4885GAA 1232/4885MAPT 4577/4885 |
| US-20090069400-A1 | Indole Sulfonamide Modulators of Progesterone Receptors | PGR, NPSR1, PRLHR | TP53 2356/4885GAA 4882/4885MAPT 4285/4885 |
| US-20240025903-A1 | Bicyclic Compounds and Uses Thereof for the Treatment of Diseases | HDGF, HGF, BDNF | TP53 331/4885GAA 384/4885MAPT 426/4885 |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | PROKR1, PROKR2, GIPR | TP53 4654/4885GAA 1110/4885MAPT 4202/4885 |
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | DGKA, DGKI, DGKG | TP53 660/4885GAA 960/4885MAPT 3573/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | TP53 4303/4885GAA 94/4885MAPT 2516/4885 |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | PROKR2, PROKR1, GIPR | TP53 4804/4885GAA 1494/4885MAPT 4090/4885 |
| US-20080070910-A1 | Therapeutic compounds and methods | SERPINB1, ABCC1, SERPINB6 | TP53 1351/4885GAA 170/4885MAPT 3357/4885 |
| US-20230331705-A1 | Fused Imidazole Derivatives as AHR Antagonists | AHR, ARNT, AIPL1 | TP53 161/4885GAA 3368/4885MAPT 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.